These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25537478)

  • 21. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
    Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.
    Zwarthoed C; El-Galaly TC; Canepari M; Ouvrier MJ; Viotti J; Ettaiche M; Viviani S; Rigacci L; Trentin L; Rusconi C; Luminari S; Cantonetti M; Bolis S; Borra A; Darcourt J; Salvi F; Subocz E; Tajer J; Kulikowski W; Malkowski B; Zaucha JM; Gallamini A
    J Nucl Med; 2017 Aug; 58(8):1249-1254. PubMed ID: 28126883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma.
    Badr S; Kotb M; Elahmadawy MA; Moustafa H
    Clin Nucl Med; 2018 Dec; 43(12):e428-e438. PubMed ID: 30358625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients.
    Chen S; Wang S; He K; Ma C; Fu H; Wang H
    Eur Radiol; 2018 Jul; 28(7):2942-2950. PubMed ID: 29383519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.
    Cheng G; Chen W; Chamroonrat W; Torigian DA; Zhuang H; Alavi A
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1469-76. PubMed ID: 21505896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
    Kasalak Ö; Glaudemans AWJM; Overbosch J; Jutte PC; Kwee TC
    Skeletal Radiol; 2018 Mar; 47(3):363-367. PubMed ID: 29124298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
    Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Littooij AS; Nievelstein RA
    Ann Oncol; 2014 May; 25(5):921-7. PubMed ID: 24351400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole body FDG-PET/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma.
    Xiao-Xue W; Xinyue H; Lijun Z
    Med Clin (Barc); 2020 Jan; 154(2):61-65. PubMed ID: 31757394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
    Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
    Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.
    Moulin-Romsee G; Hindié E; Cuenca X; Brice P; Decaudin D; Bénamor M; Brière J; Anitei M; Filmont JE; Sibon D; de Kerviler E; Moretti JL
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1095-105. PubMed ID: 20204358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
    Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
    Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
    Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter.
    Kand PG; Tiwari BP; Basu S; Asopa RV; Nayak UN
    Indian J Cancer; 2010; 47(4):380-4. PubMed ID: 21131749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.